Key points from the Australian Technical Advisory Group on Immunisation (ATAGI) clinical advice on the administration of seasonal influenza vaccines:

• Annual vaccination is the most important measure to prevent influenza and its complications. It is recommended for all people ≥6 months of age.
• All vaccinations must be recorded on the Australian Immunisation Register (AIR).
• In 2022, there was a resurgence of influenza virus circulation arising from the reopening of international borders. In 2023, seasonal influenza activity is expected to continue and the importance of influenza vaccination should be emphasised.
• Influenza vaccines can be co-administered (given on the same day) as any COVID-19 vaccine.
• For adults aged ≥65 years, both the adjuvanted (Fluad® Quad) and high dose influenza vaccine (Fluzone High Dose Quadrivalent) are preferentially recommended over standard influenza vaccine. There is no preference for use between either Fluad® Quad or Fluzone High-Dose Quadrivalent in this age group.
• If a person had a 2022 influenza vaccine in late 2022 or early 2023, they are still recommended to receive a 2023 formulation of influenza vaccine when it becomes available (likely from March 2023).